https://doi.org/10.33472/AFJBS.6.6.2024.1257-1283



ABSTRACT

Background: Oral medication administration is perhaps the most common method of the dosage form. Researchers have been encouraged by recent technological advancements to produce Fast disintegrating tablets (FDTs) to enhance patient compliance and accessibility. The study was designed to evaluate the composition and efficacy of herbal fast disintegrating tablets for headache care. Herbal powder extracts of *Salix alba L* (White Willow bark), *Tinospora cordifolia* (Guduchi), *Achyranthes aspera* (Latjira), *Cyprus rotundus* (Nagarmotha), and *Withania somnifera* (Ashwagandha) are produced and processed into fast disintegrating tablets using a super disintegrant including cross povidone, sodium starch glycolate, and micro-crystalline cellulose in various ratios.

Methods: Several pre-formulation batches (F1-F9) were formed using the direct compression method with various excipient ratios and evaluated pre and post-compression. Weight variation, hardness, friability, thickness, disintegration time, wetting time, content uniformity, in-vitro release, stability study, and IR compatibility were all evaluated on those tablets. According to ICH standards, a stability study was undertaken, and all formulations were determined to be stable. Increased solubility is observed in the UV absorption spectra.

Conclusion: F7 and F9 show excellent performance with a disintegration time of 26sec and 24sec, Content uniformity of $98.75 \pm 0.04\%$ and $98.65\pm0.43\%$, and greater dissolution rate 97.04% and 98.93% at 30 min.

Keywords: Fast disintegrating tablet, Herbal formulation, Headache, Cross povidone, Superdisintegrants, Disintegration time.

Article History

Volume 6,Issue 6, 2024 Received:20 Feb 2024 Accepted : 28 Mar 2024 doi: 10.33472/AFJBS.6.6.2024.1257-1283

1. Introduction

Fast disintegrating tablets (FDTs) have attracted a lot of attention over the last three decades because of their higher patient compliance, increased solubility, and stability characteristics compared to traditional tablets and capsules. For quick disintegration, FDTs are solid dosage forms potential implementation ingredients. to increase bioavailability and patient compliance, quick dissolving drug delivery methods are widely employed. A wide range of pharmaceutical and patient requirements are being addressed by new FDT technologies, from improved life-cycle management to comfortable dosing for dysphasic patients in pediatrics, geriatrics, and psychiatry. Because of this, the scientific and industrial communities have been spurred on to develop novel Fast dissolving formulations and technical techniques [1].

Fast disintegrating tablets (FDTs) are also known as quick disintegrating, rapid dissolve, fast dissolving, mouth dissolving, quick dissolving, rapimelt, orodispersible, orally disintegrating, effervescent drug absorption system [2].

It is estimated that these non-allopathic medical systems are used by more than 70% of India's 1 billion people. The Indian Medications Act currently does not distinguish between herbal drugs and dietary supplements. Many natural medications, on the other hand, have a large body of empirical data to support their efficacy. There is a well-established business that manufactures evidence-based herbals in accordance with pharmacopoeial recommendations. In a number of Institutes/Universities, there has been a significant amount of fundamental and clinical study on medicinal plants and their formulations [3].

As the "science of life and longevity" in Sanskrit, Ayurveda is one of the oldest medical systems focused on lifestyle, nutrition and herbs. Ayurveda, Siddha, and Unani, as well as natural goods utilized for their pharmacological activities, have all employed medicinal plants and minerals for thousands of years in various forms. Different powders developed by ayurvedic firms are commonly recommended by ayurvedic doctors [4].

Headache is a continuous symptom in everyone and is an eminent issue in youth and puberty, for what it's worth in adulthood. Headache is originated by cough, sneezing, straining, fever, or sleep; there are unusual signs on assessment and neurological or visual symptoms. An abundance or absence of sleep could cause a headache. Headache is a general and worldwide symptom with a complicated and miscellaneous set of origin. The headache itself could be hurting and disabling aspects that cause substantial levels of incapacity [5, 6].

FDTs were developed in this work to have reasonable mechanical integrity and to disintegrate in the mouth more quickly without water. MCC is utilised as a diluent in tablet formulations to accomplish this purpose. Superdisintegrants like Cross povidone, microcrystalline cellulose (MCC), sodium starch glycolate (SSG), and mixtures of cross povidone, sodium starch glycolate, and microcrystalline cellulose have been used in the formulation of tablets in an attempt to increase the dissolution rate and speed up disintegration. This composition makes use of herbal powder extracts (Table 1). It's a natural remedy for headaches [7].

Plant Name	Botanical Name	Active Constituents	Mechanism of Action	Reference
White Willow bark	Salix alba L (Salicaceae)	Salicylic glycosides, salicin, and salicortin	Inhibition of prostaglandins(PGE ₂), cyclooxygenase(COX-2)	8, 9, 10
Latjira	Achyranthes aspera (Amaranthac eae)	Linalool, Oleanolic acid glycosides, amino acids ,flavonoids, and saponins	Inhibits phospholipase A, (COX-1, COX-2)	11, 12
Guduchi	Tinospora cordifolia (Menisperma ceae)	Tinosporine, isocolumbin, flavonoids, terpenoids, glycosides, and alkaloids	Down-regulation of prostaglandins (PGE ₂), and proinflammatory cytokines (IL-1b, IL-6, TNF- α)	13, 14, 15
Nagar- motha	Cyprus rotundus (Cyperaceae)	α-cyperone, salicylic acid, catechin, quercetin,	Inhibition of cyclooxygenase (COX- 2), and interleukin (IL-6)	16, 17
Ashwa- gandha	Withania somnifera (Solanaceae)	Withaferin A, withanine, quercetin, kaempferol, and flavonoids	Inhibition of interleukin (IL-6) and tumor necrosis factor (TNF- α)	18, 19

Table 1: List of commonly	recommended Avurvedic	plants in Headache.
		1

2. Materials and Methods

The herbal powder extracts of Salix *alba L, Tinospora cordifolia*, *Achyranthes aspera, Cyprus rotundus, and Withania somnifera* was collected from Vital Herbs, Uttam nagar, Delhi, 110059. Cross povidone, Sodium starch glycolate and Microcrystalline cellulose, Citric acid monohydrate, Sodium bicarbonate, Beta-cyclo dextrin, Tartaric acid, Magnesium stearate, and Talc were obtained as gift sample from Loba Chemie Pvt Ltd Mumbai 40002.All other chemicals and reagent was of analytical grade.

2.1. Method for Preparation of Herbal Fast Disintegrating Tablets:

Direct compression technique was used to prepare herbal tablets of powder extracts using various concentrations of Microcrystalline cellulose (MCC), Cross povidone, Beta-cyclo dextrin, Sodium starch glycolate (SSG), Magnesium stearate, Sodium bicarbonate, Tartaric acid, Citric acid monohydrate, and Talc. In a glass mortar, the materials were evenly mixed. Drug and other components were well mixed before being squeezed with 0.5-mm punches in an automated tableting machine. [20, 21, 22].

Herbal powder extract	Quantity in mg
Salix alba L.	85 mg
Tinospora cordifolia	85 mg
Achyranthes aspera	60 mg
Cyprus rotundus	60 mg
Withania somnifera	60 mg
Total	350 mg

2.1.1. Formula for herbal extracts tablet preparation:

Table 4.5: Herbal extracts tablet formula

2.2. Formulation of herbal tablet by Direct Compression Method:

It is necessary to conduct a formulation design research in order to determine the most suitable excipients for manufacturing tablets. To test the varied concentrations of Microcrystaline cellulose (MCC), Sodium starch glycolate (SSG), Cross povidone, Betacyclo dextrin, Tartaric acid, Citric Acid Monohydrate, and sodium bicarbonate, we made a batch of tablets with varying concentrations of these ingredients. The experimental batches

Ingredient	F1	F2	F3	F4	F5	F6	F7	F8	F9
Extract powder of herbs	350	350	350	350	350	350	350	350	350
Cross povidone	100	100	70	60	60	60	50	50	50
Beta-cyclo dextrin	100	80	-	-	70	-	-	-	-
Sodium starch glycolate	-	-	-	-	70	-	-	-	-
Poly vinyl pyrolidone	-	-	-	-	-	-	-	-	-
Tartaric acid	-	-	_	-	-	70	-	-	-
Citric acid monohydrate	-	-	70	80	-	-	80	75	70
Sodium bi carbonate	-	-	70	70	-	70	80	75	70
Micro crystalline	50	70	40	40	50	50	40	50	60
Magnesium stearate	1%	1%	1%	1%	1%	1%	1%	1%	1%
Talc	1%	1%	1%	1%	1%	1%	1%	1%	1%
Total	600	600	600	600	600	600	600	600	600

of tablets were made utilising the direct compression technique and various excipients that were generally available at the time.

Table 4.6: Fast-disintegrating tablet ingredients include

2.3. Preparation of standard stock solution:

After dissolving 100mg of powdered herbal extract in 100ml of water, the final concentration was determined. Aliquots of the stock mixture were diluted to create concentrations between 100 and 500 μ g/ml by diluting them with 0.01N HCl. At wavelengths between 200 and 400 nanometers, the absorption peaks were found [23].

2.3.1. Determination of analytical wavelength:

The final solution, which contained 100 μ g/ml, was scanned at wavelengths between 200 and 400 nanometers. The analytical wavelength for lambda max was determined to be 281nm.

2.4. Evaluation of powder blend (Preformulation study):

Preformulation characteristics such as angle of repose, bulk density, tapped density, Hausner ratio, Carr's index, and FTIR investigations were performed on the herbal powder mix. [24, 25, 26].

2.4.1. Angle of repose: It was estimated using a funnel. A funnel collected the weighted powder. The funnel's tip now almost reaches the powder heap's apex. The funnel let the powder freely stream over the surface. The powder cone's area was calculated using the equation below.

$\theta = \tan \theta / r$

Angle of repose	Flow property
25-30	Excellent
31-35	Good
36-40	Fair
41-45	Passable
46-55	Poor
56-65	Very poor
>65	Extremely poor

Where h and r are the powder cone's height and radius, respectively.

2.4.2. Bulk Density: It's the mass-to-volume ratio of powder. It was computed by weighing powder and noting the beginning weight. The bulk volume was generated initially. Using the formula below, the bulk density was calculated.

Bulk density (Db) = Mass (M) / Bulk volume (Vb)

Where,

M is the powder's mass.

Vb is the powder's bulk volume.

2.4.3. Tapped density: It's the ratio of powder mass to tapped volume. The powder's volume was determined by tapping it 750 times and recording the tapped volume if the variation was less than 2%. It is documented if it is larger than 2%. The tapping was repeated until the loudness difference between taps was less than 2%. (in a bulk density device) It is supplied in gm/ml.

Tapped density (Dt) = Mass (M) / Tapped volume (Vt)

Where,

M - Mass of powder.

Vt - Tapped volume of the powder.

2.4.4. Carr's Index: It's a simple, rapid way to estimate powder flow parameters. Following is the formula used to determine the % compressibility of bulk medicine.

Carr's Index	Type of flow
5-15	Excellent
12-18	Good
18-23	Poor
35-38	Very poor
>40	Extremely poor

% compressibility index = Tapped bulk density – Initial bulk density × 100 Tapped bulk density

 Table : Carr's Index

2.4.5. Hausner's ratio: The Hausner ratio compares tapped to bulk density. It measures how easily a powder flows. The formula is as follows.

Hausner ratio = Tapped density (Dt) / Bulk density (Db)

Hausner's ratio	Type of flow
Less than 1.25	Good flow
1.25 - 1.5	Moderate

More than 1.5	Poor flow

Table : Hausner's ratio

2.5. Evaluation of tablets (Post compression study) : [25]

- 2.5.1. Hardness test: In a diametric compression test, hardness is defined as the force necessary to crack a tablet. The Monsanto hardness tester was used to measure it. It's measured in kg / cm². In each formulation, three tablets were chosen at random and the mean and standard deviation values were determined.
- **2.5.2.** Friability test: To test a tablet's friability, it is exposed to varied friction and shocks. The tablet was friable using the Roche friabilator. A pre-weighed sample of tablets was placed in the friabilator and spun for 100 revolutions at 25 rpm. The pills were 100 times weighed.

$$F = \frac{W \text{ initial} - W \text{ final}}{W \text{ initial}}$$

- **2.5.3. Weight variation test:** The weight variation test consisted of weighing 20 tablets separately, calculating the average, and comparing the average to the ideal.
- **2.5.4. Thickness:** A vernier calliper from an Electro lab type was used to measure the thickness of the tablets. Five pills are randomly selected from each batch. The units of measurement are millimetres, and average values have been calculated.
- **2.5.5. Content uniformity:** This test ensures that each batch has the same amount of active medicine. Each batch included 10 crushed pills. Then 100 ml of 0.1N HCl with 100 mg powdered herbal extract. To filter this solution, 1 ml was taken and diluted 100 times with 0.1N HCl. The drug concentration was determined using a UV visible spectrophotometer at 281 nm.
- **2.5.6. Wetting time:** The time taken to completely moisten a pill was recorded. Each group had three trials, with the standard deviation computed.
- **2.5.7. Disintegration test:** The time it took for the FDT to disintegrate completely was used to compute the disintegration time. Water temperature was used to track the disintegration period of six FDTs in each tube of the disintegration test device while it was 37±2°C. Results for each concentration were provided as the mean standard deviation for six pills.

- **2.5.8. Dissolution Studies:** At 37±2°C, 50 rpm, and 900 ml distilled water, the release rate of the produced tablets was measured using the USP type 2 (Paddle) procedures. The dissolving medium is replenished with 10 ml of blank media once the samples in 10 ml have been removed. A UV-Spectrophotometer at a wavelength of 281 nm collects samples every five minutes throughout the duration of the experiment and analyses them. Measuring and documenting the rate of disintegration is a need. A standard calibration plot was used to assess the herbal extract's concentration.
- **2.5.9. Kinetic data analysis:** Using such data from an in vitro diffusion investigation, the kinetics and technique of herbal extract drug release were analysed by graphing the following kinetics (zero order, first order, and Higuchi equation) and calculating release using Korsmeyer-Peppas equations.
- Zero-Order Kinetics: The cumulative drug concentration released over time was plotted.

$C = K_0 t$

Where K0 is the zero-order rate constant and t is time in hours. A straight line with K0 slope would intersect the axis origin on a concentration vs time graph.

First order kinetics: The first order logarithm of the cumulative remaining drug concentration vs passing time is used. To better understand how drugs are released from formulations, we'll look at this kinetics.

Log C = Log Co-kt / 2.303

Where C_0 represents the initial drug concentration, k represents the first order constant, and t represents the time.

Higuchi's Model: Higuchi's model as cumulative percentage of drug released vs square root of time.

$$Q = Kt1/2$$

Where,

K- The system's design variables

T- Time in hours. This model represents drug release from a swellable matrix as a square root of time dependant mechanism.

Korsemeyer-Peppas Equations: After plotting the first 60 percent of drug release on a log-log graph using the Korsemeyer equation, the exponent may be calculated from the slope of the line.

$$\mathbf{Mt} / \mathbf{M} \infty = \mathbf{Ktn}$$

Where,

 $Mt/M\infty$ - Fractional solute release,

t - Release time,

K - Kinetic constant.

The tracers' release mechanism is described by the exponent and in the drug/polymer system. The drug release mechanism is called Fickian diffusion if the exponent n is equal to or less than 0.45 for cylindrical matrix tablets, and non-Fickian or anomalous diffusion if n is more than or equal to 0.89.

2.5.10. Stability studies: The capacity of a certain formulation to retain its physiological, biochemical, pharmaceutical, and toxicological features in a given environment is characterized as drug stability in the pharmaceutical business.

Stability testing aims to demonstrate how diverse environmental factors such as light, temperature, and humidity affect a medicine product's quality over time.

Study	Storage co	Time period	
Study	Temperature (⁰ C)	Temperature (°C) Relative humidity (%)	
Long term	$250^{0}C \pm 20^{0}C$	60% ±5% RH	12
Intermediate	$300^{0}C\pm20^{0}C$	65% ±5% RH	6
Accelerated	$400^{0}C\pm20^{0}C$	75% ±5% RH	6

Table.ICH guidelines for stability study

3. Result

3.1. Characterization of extract powder: The basic characterization of powder and micromeritic properties of formulations containing polyherbal extracts powder used for preparing fast disintegrating tablets mentioned in table.

3.2. UV spectrophotometric study: UV Spectrophotometric study was conducted in 0.1N HCL pH 1.2 and examine range was set between 200-400nm. Absorption maximum (λ max) obtained in 0.1N HCL pH 1.2 was 281nm (Fig.1). The linear correlation was found to be 0.999 (Fig.2).



Fig.1: λmax scan for DVS at 281nm in 0.1N HCL

S.No.	Concentration (µg/ml)	Absorbance
1	0	0 ± 0
2	100	0.184 ± 0.01
3	200	0.386 ± 0.014
4	300	0.598 ± 0.016
5	400	0.793 ± 0.019
6	500	1.001 ± 0.02

Standard Calibration curve of herbal extract (Each value represents mean n=3, ±S.D)



Table : Standard Calibration curve of herbal extract

Fig.2 : Calibration curve in 0.1N HCL

3.3. FTIR Spectral analysis:

S. no.	Plant name	Chemical Constituent	Functional group	Observed range
			$\frac{1150}{1000}$	$(C \cap (1013 18))$
1		Salicin, and	O-H (3200-2700)	O-H(3243.2)
1	Salix alba	Salicortin	C=C (1650-1566)	C=C (1614.8)
	(Flg.5)		С-Н (2000-1650)	С-Н (1670.6)
			C-O (1150-1060)	C-O (1015.87)
2	T :	Tinosporine	C=O (1690-1650)	C=O (1622.7)
2	Tinospora	and	O-H(3700-3584)	O-H(3299.2)

	cordifolia	Isocolumbin	C=C (1650-1566)	C=C (1570)
	(Fig.4)		С-Н (2000-1650)	C-H (1680)
			CH3 (2830-2695)	CH3 (2920)
			C-O (1150-1060)	C-O (1023.57)
2		Oleanolic	O-H(3700-3584)	O-H(3765.7)
3	Achyranthes	acid and	C=C (1650-1566)	C=C (1596.9)
	aspera	Linalool	С-Н (2000-1650)	С-Н (1432)
	(Fig.5)		COO(1770-1780)	COO(1733.2)
			CH3 (2830-2695)	CH3 (2824.90)
			C-O (1150-1060)	C-O (1020.02)
	G	Quercetin	O-H(3700-3584)	O-H(3310)
4	Cyprus	and	C=C (1650-1566)	C=C (1514.4)
	rotunaus	Salicylic	С-Н (2000-1650)	C-H (1490)
	(Flg.0)	acid	C=O (1690-1650)	C=O (1618.4)
			C-O (1150-1060)	C-O (1019.99)
-	TT 7: 1	Withaferin A	O-H(3700-3584)	O-H(3224.52)
5	5 Withania somnifera (Fig.7)	and	C=C (1650-1566)	C=C (1420.34)
		Withanine	C=O (1690-1650)	C=O (1656.08)
			С-Н (2000-1650)	С-Н (1515)
			CH3 (2830-2695)	CH3 (2850)

Table:	FTIR	Spectral	analysis







Fig.4 : FTIR of Tinospora cordifolia







Fig.6 : FTIR of Cyprus rotundus







Fig.8 : FTIR of all Herbal extract



Fig.9 : FTIR of all Herbal extract and Excipients (Cross povidone, Sodium bicarbonate, Micro crystalline cellulose, Magnesium stearate, Talc, Citric acid, and Corn starch)



Fig.10 : FTIR of F7



Fig.11 : FTIR of F9

- **3.4. Partition coefficient:** The partition coefficient of a mixture of Willow bark, Guduchi, Latjira, Nagarmotha, and Ashwagandha were calculated. In the oil phase, the concentration of the herbal extract was found to be 4.69mg while in the aqueous phase was 5.31mg. Hence, the partition coefficient of the herbal extract was 0.883.
- **3.5. pH determination:** A pH of herbal extract was 2.8 reported in 1mg/ml concentration in a 0.1N HCl.
- **3.6.** Solubility analysis: 0.1N HCl, ethanol, and methanol are all solvents that can dissolve herbal extract powder samples.

Name of the plant	Nature	Color	Odour	Taste
Salix alba L	Fine powder	Pale yellow	Characteristic	Bitter
Tinospora cordifolia	Fine powder	brown	Characteristic	Astringent
Achyranthes aspera	Fine powder	Pale green	Characteristic	bitter
Cyprus rotundus	Fine powder	Brown	Characteristic	Astringent
Withania somnifera	Fine powder	Yellow	Characteristic	Astringent

3.7. Observation of morphological characters:

Table: Observation of morphological characters

Formulation	Angle of	Bulk	Tapped	Carr's	Hausner'
	repose (θ)	density	density	index (%)	s ratio
		(gm/cm ³)	(gm/cm ³)		
F1	19.40±0.25	2.74±0.14	3.31±0.56	17.22±0.25	1.20±1.45
F2	19.53±0.78	2.67±1.56	3.23±0.86	17.33±0.89	1.20±0.36
F3	19.92±1.56	2.73±0.28	3.30±0.78	17.27±0.25	1.20±0.85
F4	19.50±1.29	2.68±1.56	3.25±0.71	17.53±1.03	1.21±1.15
F5	19.48±0.93	2.61±0.45	3.16±1.02	17.40±0.57	1.21±1.09
F6	19.26±0.37	2.64±0.52	3.19±1.58	17.24±1.01	1.20±1.15
F7	19.29±0.69	2.60±1.08	3.15±1.84	17.46±1.59	1.21±1.64
F8	19.54±0.53	2.69±1.43	3.26±0.98	17.48±0.14	1.21±0.95
F9	19.23±0.41	2.66±0.82	3.21±0.29	17.13±0.54	1.20±0.83

3.8. Evaluation of powder characteristics:

Data as expressed as mean \pm S.D. (n = 3)

Table: Evaluation of powder characteristics

3.9.	Post compression e	evaluation of tablets:	
------	--------------------	------------------------	--

Formulati on	Weight variation	Hardness kg/cm2	Friability (%)	Thickness (mm)	Content uniformity	Wetting time
	(mg)				(%)	(sec)
F1	574±3.25	4.3±0.35	0.17±0.12	6.58±0.12	90.23±0.09	134
F2	559±1.65	4.0±1.25	0.29±0.02	6.61±0.23	90.52±0.23	109
F3	594±5.23	4.2±1.02	0.74±0.68	6.45±0.12	96.24±0.02	81
F4	589±1.47	3.3±0.27	0.51±0.74	6.38±0.03	95.63±0.08	61
F5	600±1.32	3.9±0.22	0.73±0.96	5.33±0.36	94.26±0.19	49
F6	602±0.57	3.2±0.52	0.64 ± 0.85	6.40±0.19	96.69±0.67	41
F7	598±1.65	3.6±0.84	0.89±0.92	6.31±0.07	98.75±0.04	26
F8	593±0.98	3.4±0.91	0.75±0.74	6.38±0.13	97.67±0.28	30
F9	600±0.82	3.8±0.43	0.93±0.28	6.32±0.16	98.65±0.43	23

Data as expressed as	mean ± S.D.	(n = 3)
----------------------	-------------	---------

Table 5.9: Post compression evaluation of tablets

Formulation	Disintegration time (sec)	Dissolution (% drug release in minute)					
		5 min	10 min	15 min	20 min	25 min	30 min
F1	160	38.56	44.15	50.25	54.95	59.67	64.48
F2	90	44.25	49.21	53.14	59.65	64.25	68.25
F3	79	48.95	55.35	62.36	68.35	72.05	75.23
F4	54	70.01	78.26	84.02	85.74	85.89	86.08
F5	35	71.27	78.04	86.27	88.19	90.96	90.05
F6	29	72.01	79.45	87.98	88.63	89.32	89.68
F7	26	73.85	80.58	89.94	92.25	95.87	97.04
F8	31	70.59	79.57	89.79	91.37	95.08	95.58
F9	24	74.48	81.69	90.05	93.97	96.87	98.93

Data as expre	ssed as mean	± S.D.	(n = 3)
---------------	--------------	--------	---------

Formulation	Zero order R ²	First order R ²	Higuchi model R ²	Korsemeyer peppas equation
F 7	0.999	0.996	0.981	0.958
F 9	0.996	0.984	0.993	0.981

3.10. Kinetic data analysis of in-vitro herbal extracts release data of F7 and F9



Fig.: Herbal extracts release kinetics of F7



Figure: Herbal extracts release kinetics of F9

5.11. Stability study of herbai fast disintegrating tabl	3.11.	Stability study	y of herbal	fast disintegr	ating tablets:
---	-------	-----------------	-------------	----------------	----------------

Parameter	Initial	1 Month	2 Month
Avg. weight (mg)	600 ± 0.82	601 ± 0.75	601 ± 0.98
Hardness (kg/cm2)	3.8 ± 0.43	3.9 ± 0.52	3.9 ± 0.79
Friability (%)	0.93 ± 0.35	0.94 ± 0.48	0.94 ± 0.43
Disintegration time (sec)	24	25	25
Wetting time (sec)	23	25	26
% Content uniformity	98.65 ± 0.43	98.78 ± 0.58	98.86 ± 0.67

Data as expressed as mean \pm S.D. (n = 3)

Table: Stability study of herbal fast disintegrating tablets

4. Discussion and Conclusion

Medicinal plants are considered to gold mine of components that are considered to be therapeutically active. These medicinal herbs are used since ancient time for treatment of many ailments. In most of the cases weather we are discussing traditional system of medicine, folklore practice or, Ayurveda combination of herbal components is one on of the widely used preparation. These preparations are intended to be used for treatment of various ailments and are considered to be polyherbal formulations.

Headache is one of the most common disorders in today's lifestyle. In this concern present study was designed to investigate analgesic potential of a polyherbal formulation consisting of three medicinal plant's extract that are reported to have good analgesic potential. *Salix alba L, Tinospora cordifolia, Achyranthes aspera, Cyprus rotundus, and Withania somnifera* were the medicinal plants that were selected for present study. A different combination of these medicinal plants plays an important role, providing synergistic activity against the disorders. Selected combination was fabricated to fast dissolving tablet and it was further evaluated and characterized on various parameters.

FDTs formulation containing 600 mg of all-herbal powder extract for headaches was the primary goal of this study, which included the development of FDTs containing excipients like Cross povidone, Citric acid monohydrate, Magnesium stearate, Beta-cyclo dextrin and Sodium starch glycolate as well as Talc as excipients. Fast disintegrating drug delivery system improved the bioavailability and therapeutic efficiency of herbal extract powder.

In the pre-formulation step, an FTIR analysis of pure herbal extract powder and excipients was performed. There hasn't been any interaction. As a result, it was discovered that herbal extracts powder is acceptable with excipients.

The direct compression method was used to prepare twenty-one batches of the formulation. The formulation angle of repose values ranges from 19.40 ± 0.25 to 19.23 ± 0.41 . The compressibility index was calculated using bulk and tapped densities. Formulation bulk and tapped values vary from 2.74 ± 0.14 to 2.66 ± 0.82 and 3.31 ± 0.56 to 3.21 ± 0.29 , consequently. For formulas, the car's index and Hausner's ratio values vary from 17.22 ± 0.25 to 17.13 ± 0.54 and 1.20 ± 1.45 to 1.20 ± 0.83 , consequently. As a result, all of the formulations had good flow characteristics.

The thickness, weight variation, hardness, friability, and drug content consistency of the manufactured FDTs were all examined. Tablet thickness varied between 6.58 ± 0.12 to 6.32 ± 0.16 in all formulations. In all formulations, the weight variation of tablets ranged

from 574±3.25 to 600±0.82. All of the formulations F1-F9 had hardness and friability of 4.3±0.35 to 3.8 ± 0.43 and 0.17 ± 0.12 to 0.93 ± 0.28 , consequently. All of the formulations had drug content varying from 90.23±0.09 to 98.65±0.43. All of the formulations had different wetting times, varying from 23 sec to 134 sec.

Compared to all formulations F7 and F9 showed the best, the disintegration time for F7 and F9 were found to be 26sec and 24sec containing cross povidone, Citric acid monohydrate, Sodium bicarbonate, and Micro crystalline cellulose.

The manufactured tablets were then put through a dissolution test to see how well they released the medication in-vitro. The dissolution tests were performed at 37 ± 0.5 °C. in 0.1N HCl in a USP type-2 apparatus. The dissolution investigations revealed that the conc. of excipients had a significant impact on the herbal extracts release from the tablets. In comparison to the other formulations, F7 and F9 had better herbal extracts release and disintegration performances. It took 24 sec and 26 sec for this formulation to disintegrate.

The drug release followed zero-order kinetics followed by non-fickian diffusion in the F7 and F9 formulations, according to the kinetic analysis.

The formulation stability tests were carried out for two months at 45° C and 175 % RH. There was no discernible difference, according to the data.

According to the results of the study, F7 and F9 were the best formulations, with disintegration times of 26 sec and 24 sec, and drug release rates of 98.93 % and 97.04 % in 30 minutes, consequently. Yet, more in-vivo research can be done to back up the findings.

When compared to a Clove analgesic tablet [24], our herbal tablet has a disintegration time of 24 sec and a drug content of 98%, whereas the clove tablet has a disintegration time of 142 sec and a drug content of 95%.

When comparing the Diclofenac potassium fast dissolving tablet [27] to our five herbal extract tablets, the diclofenac potassium fast dissolving tablet dissolves in 25.33 sec with serious side effects, whereas our five herbal extract tablet dissolves in 24 sec with no or minor health consequences.

Overall, the FDTs are made from a combination of *Salix alba L, Tinospora cordifolia, Achyranthes aspera, Cyprus rotundus,* and *Withania somnifera* extract powder and excipients give a stable formulation that meets performance standards. In in-vivo studies, this formulation has strong analgesic promise for headaches.

References

- 1. Sreenivas SA, Dandagi PM, Gadad AP, Godbole AM, Hiremath SP, Mastiholimath VS, Bhagawati ST. Orodispersible tablets: New-fangled drug delivery system-A review. Indian Journal of Pharmaceutical Education. 2005 Oct;39(4):177.
- 2. Sharma D. Formulation development and evaluation of fast disintegrating tablets of salbutamol sulphate for respiratory disorders. International Scholarly Research Notices. 2013;2013.
- 3. Vaidya AD, Devasagayam TP. Current status of herbal drugs in India: an overview. Journal of clinical biochemistry and nutrition. 2007;41(1):1-1.
- 4. Dixit PK, Mittal S. A Comprehensive Review on Herbal Remedies of Diuretic Potential. International Journal of Research in Pharmacy & Science. 2013 Jan 1;3(1).
- 5. Terrin A, Toldo G, Ermani M, Mainardi F, Maggioni F. When migraine mimics stroke: a systematic review. Cephalalgia. 2018 Dec;38(14):2068-78.
- WAL A, WAL P, SHUKLA S, SRIVASTAVA A. A Comprehensive Review on the Medicinal Plants for the Treatment of Headache. International Journal of Pharmaceutical Research. 2021 Jul;13(3).
- 7. Kagalkar AA, Nanjwade BK, Bagli RS. Development and evaluation of herbal fast dissolving tablets of Tectona grandis Linn. International Journal of Pharma Research & Review. 2014 Jan;3(1):6-14.
- 8. Wagner I, Greim C, Laufer S, Heide L, Gleiter CH. Influence of willow bark extract on cyclooxygenase activity and on tumor necrosis factor alpha or interleukin 1 beta release in vitro and ex vivo. Clinical pharmacology and therapeutics. 2003 Mar 1;73(3):272-4.
- 9. Mao P, Liu Z, Xie M, Jiang R, Liu W, Wang X, Meng S, She G. Naturally occurring methyl salicylate glycosides. Mini reviews in medicinal chemistry. 2014 Jan 1;14(1):56-63.
- 10. Panaite TD, Saracila M, Papuc CP, Predescu CN, Soica C. Influence of dietary supplementation of Salix alba bark on performance, oxidative stress parameters in liver and gut microflora of broilers. Animals. 2020 Jun;10(6):958.
- Rehman R, Melki D, Shehzad A, Nadeem F, Khalid T. Commercial importance, medicinal value and therapeutic potentials of chaff flower (achyranthes aspera)–a review. International Journal of Chemical and Biochemical Sciences. 2018;14:62-70.
- 12. Singh N, Mrinal PS, Gupta VK. A Review on Pharmacological Aspects of Achyranthes Aspera. Int J Pharmacogn Chinese Med. 2019;3(4):000188.
- 13. Sannegowda KM, Venkatesha SH, Moudgil KD. Tinospora cordifolia inhibits autoimmune arthritis by regulating key immune mediators of inflammation and bone damage. International journal of immunopathology and pharmacology. 2015 Dec;28(4):521-31.
- 14. Preeti S. Tinospora cordifolia (Amrita)-a miracle herb and lifeline to many diseases. International Journal of Medicinal and Aromatic Plants. 2011;1(2):57-61.
- Gautam A, Kaur H, Kaur A, Prashar PK, Sood A, Singh SK, Gulati M, Pandey NK, Kumar B. Tinospora cordifolia: A Successful Story from Botanical background to Pharmaceutical Product. Research Journal of Pharmacy and Technology. 2020 Nov 13;13(11):5620-30.

- Nagulendran KR, Velavan S, Mahesh R, Begum VH. In vitro antioxidant activity and total polyphenolic content of Cyperus rotundus rhizomes. E-journal of Chemistry. 2007 Jul;4(3):440-9.
- 17. Kajaria D, Tripathi JS, Pandey BL. The analgesic and anti-inflammatory activities of the hydroalcholic extract of" Shirishadi compound" in animal model. Journal of Applied Pharmaceutical Science. 2011 Dec 1;1(10):98.
- Minhas U, Minz R, Bhatnagar A. Prophylactic effect of Withania somnifera on inflammation in a non-autoimmune prone murine model of lupus. Drug discoveries & therapeutics. 2011 Aug 31;5(4):195-201.
- 19. Minhas U, Minz R, Das P, Bhatnagar A. Therapeutic effect of Withania somnifera on pristane-induced model of SLE. Inflammopharmacology. 2012 Aug;20(4):195-205.
- 20. Parkash V, Maan S, Deepika SK, Hemlata VJ. Fast disintegrating tablets: Opportunity in drug delivery system. Journal of advanced pharmaceutical technology & research. 2011 Oct;2(4):223.
- 21. Hirave RV, Code QR. Development & evaluation of herbal fast dissolving tablet of Capparis divaricata Lam. International Journal of Advance in Pharmaceutics. 2017;6:24-30.
- 22. Singh VK, Maurya JK, Mishra P, Singh PK, Mishra V. Formulation and Evaluation of Mouth Dissolving Tablet of Norfloxacin with Piperine and their Antibacterial Activity.
- 23. Pharmacopoeia I. Government of India, ministry of health and family welfare. Delhi: Controller of Publications. 1996;2(35):448.
- 24. Tiwari RK, Singh L, Sharma V, Singh P. Formulation development of fast dissolving tablet of clove-the best nutraceutical analgesic tablet. Asian Food Science Journal. 2018;1(3):1-7.
- 25. Maurya HA, Kumar TI. Formulation, standardization, and evaluation of polyherbal dispersible tablet. Int J App Pharm. 2019;11(1):158-67.
- 26. Diyya AS, Thomas NV. "FORMULATION AND EVALUATION OF FUROSEMIDE FAST DISSOLVING TABLETS." (2019).
- 27. Karthikeyan M, Umarul MA, Megha M, Shadeer HP. Formulation of diclofenac tablets for rapid pain relief. Asian Pacific Journal of Tropical Biomedicine. 2012 Jan 1;2(1):S308-11.